A new research paper was published in Oncotarget, titled, "Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell ...

Dysphagia in cancers of the lip, oral cavity, and pharynx patients: Impact on cachexia, hospitalization, and racial disparities on outcomes. This is an ASCO Meeting Abstract from the 2025 ASCO Annual ...

Preclinical study results suggest that targeting Hippo signaling may help address treatment resistance in acute myeloid ...

Researchers at The University of Texas MD Anderson Cancer Center have discovered that an investigational epigenetic therapy ...

A novel epigenetic therapy has demonstrated activity against treatment-resistant acute myeloid leukaemia in preclinical ...

TP53 mutations are crucial in cancer development and treatment response, influenced by genetic and environmental factors. In CLL and AML, TP53 serves as a significant prognostic marker, affecting ...

Acute myeloid leukemia (AML) is a rare and aggressive hematologic malignancy. AML progresses rapidly and is indicated by an excess of immature white blood cells. It is caused by high mutational burden ...

Despite the significance of immune checkpoint inhibitors (ICIs) in solid tumor treatment, identifying ICI-sensitive populations remains a challenge. Mutations in DNA damage response (DDR) pathway ...

Imagine a tiny superhero inside every cell of your body whose job is to stop damaged cells before they turn dangerous. That superhero is a gene called TP53, and for decades scientists have known it as ...